医学文献 >>
  • 检索发现
  • 增强检索
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
默认
×
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

Potential treatment approaches for malignant peritoneal mesothelioma:in vivo and in vitro experimental study of natural killer cell immunotherapy

摘要Objective:Malignant peritoneal mesothelioma(MPM)is a rare primary malignant tumor with an extremely poor prognosis that currently lacks effective treatment options.This study investigated the in vitro and in vivo efficacy of natural killer(NK)cells for treatment of MPM.Methods:An in vitro study was conducted to assess the cytotoxicity of NK cells from umbilical cord blood to MPM cells with the use of a high-content imaging analysis system,the Cell Counting Kit-8 assay,and Wright-Giemsa staining.The level of NK cell effector molecule expression was detected by flow cytometry and enzyme-linked immunosorbent assays.The ability of NK cells to kill MPM cells was determined based on live cell imaging,transmission electron microscopy,and scanning electron microscopy.An in vivo study was conducted to assess the efficacy and safety of NK cell therapy based on the experimental peritoneal cancer index,small animal magnetic resonance imaging,and conventional histopathologic,cytologic,and hematologic studies.Results:NK cells effectively killed MPM cells through the release of effector molecules(granzyme B,perforin,interferon-γ,and tumor necrosis factor-α)in a dose-and density-dependent manner.The NK cell killing process potentially involved four dynamic steps:chemotaxis;hitting;adhesion;and penetration.NK cells significantly reduced the tumor burden,diminished ascites production,and extended survival with no significant hematologic toxicity or organ damage in NOG mice.Conclusions:NK cell immunotherapy inhibited proliferation of MPM cells in vitro and in vivo with a good safety profile.

更多
广告
作者 Heliang Wu [1] Yi Wang [2] Yulin Lin [3] Ru Ma [4] Xuemei Du [5] Yandong Su [4] Rui Yang [4] Zhiran Yang [4] Xinli Liang [4] Yinguang Zhang [6] Xiaoqing Liang [7] Zhonghe Ji [4] Chunning Lai [8] Yajing Huang [8] Yan Li [1] 学术成果认领
作者单位 Department of Peritoneal Cancer Surgery,Beijing Shijitan Hospital,Peking University Ninth School of Clinical Medicine,Beijing 100038,China;Department of Peritoneal Cancer Surgery,Beijing Shijitan Hospital,Capital Medical University,Beijing 100038,China;Department of Surgical Oncology,Beijing Tsinghua Changgung Hospital,Tsinghua University,Beijing 102218,China [1] Department of Hematology,Fifth Medical Center of Chinese PLA General Hospital,Beijing 100071,China [2] Department of Thoracic Surgery,Zhongshan Hospital,Fudan University(Xiamen Branch),Xiamen 361015,China [3] Department of Peritoneal Cancer Surgery,Beijing Shijitan Hospital,Capital Medical University,Beijing 100038,China [4] Department of Pathology,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China [5] Department of Thoracic Surgery,Beijing Tiantan Hospital,Capital Medical University,Beijing 100070,China [6] Department of Oncology,Beijing Shijitan Hospital,Capital Medical University,Beijing 100038,China [7] Innovvy Biomedical Technology Co.,Ltd.,Beijing 100195,China [8]
栏目名称
DOI 10.20892/j.issn.2095-3941.2024.0218
发布时间 2024-12-31(万方平台首次上网日期,不代表论文的发表时间)
提交
  • 浏览6
  • 下载1
癌症生物学与医学(英文版)

癌症生物学与医学(英文版)

2024年21卷11期

1078-1094页

SCIMEDLINEISTICCSCDCABP

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

法律状态公告日 法律状态 法律状态信息

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new医文AI 翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷